Table 2.
Descriptive statistics of study phase I sensitivity measures (type 1 and type 2) and reaction times (type 1 and type 2) by drug and encoding level.
| Measure | Placebo (n = 29) |
Ketamine (n = 24) |
||
|---|---|---|---|---|
| M | SD | M | SD | |
| Type 1 performance (d')a | ||||
| Deep vs. new | 2.11 | 0.63 | 1.94 | 0.49 |
| Shallow vs. new | 0.85 | 0.38 | 0.74 | 0.37 |
| Type 2 sensitivity (meta-d')a,b | ||||
| Deep vs. new | 2.41 | 0.95 | 2.06 | 0.72 |
| Shallow vs. new | 0.89 | 0.49 | 0.58 | 0.39 |
| Type 2 efficiency (meta-d'/d') | ||||
| Deep vs. new | 1.17 | 0.38 | 1.13 | 0.48 |
| Shallow vs. new | 1.15 | 0.61 | 0.92 | 0.69 |
| Type 1 reaction times (in ms)a | ||||
| Deep | 1415.66 | 216.69 | 1458.75 | 189.0 |
| Shallow | 1572.63 | 197.31 | 1576.0 | 174.66 |
| New | 1600.11 | 227.04 | 1549.02 | 152.33 |
| Type 2 reaction times (in ms)a | ||||
| Deep | 1592.22 | 210.58 | 1578.45 | 221.79 |
| Shallow | 1670.7 | 229.7 | 1698.43 | 297.13 |
| New | 1755.37 | 251.38 | 1731.03 | 284.39 |
M, mean; ms, milliseconds; SD, standard deviation.
a
Significant effects of encoding level.
b
Significant effects of drug.